LOGIN  |  REGISTER
Viking Therapeutics
Viking Therapeutics

Integer to Participate in Citi's 2023 European Healthcare Conference

June 15, 2023 | Last Trade: US$130.42 1.07 -0.81

PLANO, Texas, June 15, 2023 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that Joe Dziedzic, President and Chief Executive Officer, and Andrew Senn, Senior Vice President, Strategy, Business Development, and Investor Relations, will participate in Citi's 2023 European Healthcare Conference, which will be held at the Citigroup Centre, 33 Canada Square, London, England, beginning at 8:00 a.m. British Summer Time (3:00 a.m. Eastern Time), on Tuesday, June 20, 2023.

About Integer®

Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, vascular, portable medical and orthopedics markets. The Company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, the Company develops batteries for high-end niche applications in energy, military, and environmental markets. The Company's brands include Greatbatch Medical®, Lake Region Medical® and Electrochem®. Additional information is available at www.integer.net.

Investor Relations:Media Relations:
Andrew SennKelly Butler
This email address is being protected from spambots. You need JavaScript enabled to view it.This email address is being protected from spambots. You need JavaScript enabled to view it.
763.951.8312214.618.4216

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB